Synergistic antitumor effects of a combination of interferon and tamoxifen on estrogen receptor-positive and receptor-negative human tumor cell lines in vivo and in vitro

Journal of Interferon and Cytokine Research

Volumn 17, Issue 11, 1997, Pages 681-693

  Lindner, Daniel J ^a,b   Borden, Ernest C ^a  

^a UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^b MEDICAL COLLEGE OF WISCONSIN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA2A INTERFERON; BETA INTERFERON; ESTROGEN RECEPTOR; TAMOXIFEN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER; BREAST TUMOR; CANCER CHEMOTHERAPY; CANCER IMMUNOTHERAPY; FEMALE; HUMAN TISSUE; MOUSE; NONHUMAN; PRIORITY JOURNAL;

ANIMALIA; MINK CELL FOCUS-FORMING VIRUS; MUS MUSCULUS;

EID: 0030680176     PISSN: 10799907     EISSN: None     Source Type: Journal    
DOI: 10.1089/jir.1997.17.681     Document Type: Article

References (37)

1. VON WUSSOW, P., JAKSCHIES, D., FREUND, M., and DEICHER, H. (1989). Humoral response to recombinant interferon-alpha 2b in patients receiving recombinant interferon-alpha 2b therapy. J. Interferon Res. 9, S25-S31.
2. CASATO, M., ANTONELLI, G., MAGGI, F., PUCILLO, L.P., DI LULLO, L., LEONI, M., CURRENTI, M., DIANZANI, F., and BONOMO, L. (1994). Resistance to recombinant alpha interferon therapy in idiopathic mixed cryoglobulinemia: reinduction of remission by natural alpha interferon both in antibody-positive and -negative patients. J. Biol. Regul. Homeostatic Agents 8, 56-59.
3. OSTLUND, L., EINHORN, S., and ROBERT, K.H. (1986). Induction of 2′,5′-oligoadenylate synthetase and blast transformation in primary chronic lymphocytic leukemia cells following exposure to interferon in vitro. Cancer Res. 46, 2160-2163.
4. FENG, G.S., DAI, W., GUPTA, S.L., WERNER-FELMAYER, G., WACHTER, H., TAKIKAWA, O., and TAYLOR, M.W. (1991). Analysis of interferon-gamma resistant mutants that are possibly defective in their signaling mechanism. Mol. Gen. Genet. 230, 91-96.
5. PETRICOIN, E., DAVID, M., FANG, H., GRIMLEY, P., LARNER, A.C., and VANDE POL, S. (1994). Human cancer cell lines express a negative transcriptional regulator of the interferon regulatory factor family of DNA binding proteins. Mol. Cell. Biol. 14, 1477-1486.
6. KOLLA, V., LINDNER, D.J., XIAO, W., BORDEN, E.C., and KALVAKOLANU, D.V. (1996). Modulation of interferon (IFN)-inducible gene expression by retinoic acid. Upregulation of STAT1 protein in IFN-unresponsive cells. J. Biol. Chem. 271, 10508-10514.
7. KALVAKOLANU, D.V., BANDYOPADHYAY, S.K., HARTER, M.L., and SEN, G.C. (1991). Inhibition of interferon-inducible gene expression by adenovirus E1A proteins: block in transcriptional complex formation. Proc. Natl. Acad. Sci. USA 88, 7459-7463.
8. ROUTES, J.M., LI, H., BAYLEY, S.T., RYAN, S., and KLEMM, D.J. (1996). Inhibition of IFN-stimulated gene expression and IFN induction of cytolytic resistance to natural killer cell lysis correlate with E1A-p300 binding. J. Immunol. 156, 1055-1061.
9. FOSTER, G.R., ACKRILL, A.M., GOLDIN, R.D., KERR, I.M., THOMAS, H.C., and STARK, G.R. (1991). Expression of the terminal protein region of hepatitis B virus inhibits cellular responses to interferons alpha and gamma and double-stranded RNA. Proc. Natl. Acad. Sci. USA 88, 2888-2892.
10. hopTum-1 Jak kinase causes leukemia-like hematopoietic defects. EMBO J. 14, 1412-1420.
11. JORDAN, V.C., and MURPHY, C.S. (1990). Endocrine pharmacology of antiestrogens as antitumor agents. Endocrine Rev. 11, 578-610.
12. LIPPMAN, M.E., and BOLAN, G. (1975). Oestrogen-responsive human breast cancer in long-term tissue culture. Nature 256, 593-595.
13. GIBSON, D.F.C., JOHNSON, D.A., GOLDSTEIN, D., LANGANFAHEY, S.M., BORDEN, E.C., and JORDAN, V.C. (1993). Human recombinant IFN-beta ser and tamoxifen: growth suppressive effects for the human breast carcinoma MCF-7 grown in the athymic mouse. Breast Cancer Res. Treat. 25, 141-150.
14. BEZWODA, W.R., and MEYER, K. (1990). Effect of alpha-interferon, 17 beta-estradiol, and tamoxifen on estrogen receptor concentration and cell cycle kinetics of MCF-7 cells. Cancer Res. 50, 5387-5391.
15. VAN DEN BERG, H.W., LEAHEY, W.J., LYNCH, M., CLARKE, R., and NELSON, J. (1987). Recombinant human interferon alpha increases oestrogen receptor expression in human breast cancer cells (ZR-75-1) and sensitizes them to the anti-proliferative effects of tamoxifen. Br. J. Cancer 55, 255-257.
16. SICA, G., NATOLI, V., STELLA, C., and DEL-BIANCO, S. (1987). Effect of natural beta-interferon on cell proliferation and steroid receptor level in human breast cancer cells. Cancer 60, 2419-2423.
17. MARTH, C.H., MAYER, I., BOCH, G., GASTL, G., HUBER, C., FLENER, R., and DAXENBICHLER, G. (1985). Effects of human interferon alpha-2 and gamma on proliferation, estrogen receptor content, and sensitivity to anti-estrogens of cultured breast cancer cells. In: The Interferon System. F. Dianzani and G.B. Lossi (eds.) New York: Raven Press, p. 367-371.
18. KAUPPILA, A., CANTELL, K., JANNE, O., KOKKO, E., and VIHKO, R. (1982). Serum sex steroid and peptide hormone concentrations, and endometrial estrogen and progestin receptor levels during administration of human leukocyte interferon. Int. J. Cancer 29, 291-294.
19. GOLDSTEIN, D., BUSHMEYER, S.M., WITT, P.L., JORDAN, V.C., and BORDEN, E.C. (1989). Effects of type I and type II interferons on cultured human breast cells: interaction with estrogen receptors and with tamoxifen. Cancer Res. 49, 2698-2702.
20. PORZSOLT, F., OTTO, A.M., TRAUSCHEL, B., BUCK, C., WAWER, A.W., and SCHONENBERGER, H. (1989). Rationale for combining tamoxifen and interferon in the treatment of advanced breast cancer. J. Cancer Res. Clin. Oncol. 115, 465-469.
21. REDDEL, R.R., MURPHY, L.C., HALL, R.E., and SUTHERLAND, R.L. (1985). Differential sensitivity of human breast cancer cell lines to the growth-inhibitory effects of tamoxifen. Cancer Res. 45, 1525-1531.
22. HOLT, J.A., WAGGONER, S.E., LEE, E.Y., HUBBY, M.M., and HAMILTON, T.C. (1987). Serum CA 125 and survival of mice inoculated with ovarian carcinoma and treated with antiestrogen, estrogen, or progestin. Gynecol. Oncol. 27, 282-293.
23. BREEN, B., and LEAKE, R.E. (1987). Steroid Hormones: A Practical Approach. Oxford: IRL Press, pp. 213-214.
24. WAKELING, A.E. (1989). Comparative studies on the effects of steroidal and nonsteroidal oestrogen antagonists on the proliferation of human breast cancer cells. J. Steroid Biochem. 34, 183-188.
25. SKEHAN, P., STORENG, R., SCUDIERO, D., MONKS, A., McMAHON, J., VISTICA, D., WARREN, J.T., BOKESCH, H., KENNEY, S., and BOYD, M.R. (1990). New colorimetric cytotoxicity assay for anticancer-drug screening. J. Natl. Cancer Inst. 82, 1107-1112.
26. CHOU, T.C., and TALALAY, P. (1984). Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv. Enz. Regul. 22, 27-55.
27. SPECTOR, S.A., TYNDALL, M., and KELLEY, E. (1982). Effects of acyclovir combined with other antiviral agents on human cytomegalovirus. Am. J. Med. 73, 36-39.
28. LINDNER, D.J., KOLLA, V., KALVAKOLANU, D.V., and BORDEN, E.C. (1997). Tamoxifen enhances interferon-regulated gene expression in breast cancer cells. Mol. Cell. Biochem. 167, 169-177.
29. GRENMAN, S.E., VAN DYKE, D.L., WORSHAM, M.J., ENGLAND, B., McCLATCHEY, K.D., HOPKINS, M., BABU, V.R., GRENMAN, R., and CAREY, T.E. (1990). Phenotypic characterization, karyotype analysis and in vitro tamoxifen sensitivity of new ER-negative vulvar carcinoma cell lines, UM-SCV-1A and UMSCV-1B. Int. J. Cancer 45, 920-927.
30. GRENMAN, S.E., WORSHAM, M.J., VAN DYKE, D.L., ENGLAND, B., McCLATCHEY, K.D., BABU, V.R., ROBERTS, J.A., MAENPAA, J., and CAREY, T.E. (1990). Establishment and characterization of UM-EC-2, a tamoxifen-sensitive, estrogen receptor-negative human endometrial carcinoma cell line. Gynecol. Oncol. 37, 188-199.
31. WEBER, C.J., MARVIN, M., KREKUN, S., KOSCHITZKY, T., KARP, F., BENSON, M., and FEIND, C.R. (1990). Effects of tamoxifen and somatostatin analogue on growth of human medullary, follicular, and papillary thyroid carcinoma cell lines: tissue culture and nude mouse xenograft studies. Surgery 108, 1065-1071.
32. CROXTALL, J.D., EMMAS, C., WHITE, J.O., CHOUDHARY, Q., and FLOWER, R.J. (1994). Tamoxifen inhibits growth of oestrogen receptor-negative A549 cells. Biochem. Pharmacol. 47, 197-202.
33. CHARLIER, C., CHARIOT, A., ANTOINE, N., MERVILLE, M.P., GIELEN, J., and CASTRONOVO, V. (1995). Tamoxifen and its active metabolite inhibit growth of estrogen receptor-negative MDA-MB-435 cells. Biochem. Pharmacol. 49, 351-358.
34. SIDKY, Y.A., and AUERBACH, R. (1975). Lymphocyte-induced angiogenesis: a quantitative and sensitive assay of the graft-vs.-host reaction. J. Exp. Med. 141, 1084-1100.
35. SIDKY, Y.A., and BORDEN, E.C. (1987). Inhibition of angiogenesis by interferons: effects on tumor- and lymphocyte-induced vascular responses. Cancer Res. 47, 5155-5161.
36. SINGH, R.K., GUTMAN, M., BUCANA, C.D., SANCHEZ, R., LLANSA, N., and FIDLER, I.J. (1995). Interferons alpha and beta down-regulate the expression of basic fibroblast growth factor in human carcinomas. Proc. Natl. Acad. Sci. USA 92, 4562-4566.
37. GAGLIARDI, A., and COLLINS, D.C. (1993). Inhibition of angiogenesis by antiestrogens. Cancer Res. 53, 533-535.